Page 1

Investigation Report on China Insulin Lispro Market, 2009-2018 Reportstack Reportstack Contact contactus@reportstack.com


Summary ď ś According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries. ď ś The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name "Humalog") was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion. ď ś Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market. Reportstack Contact contactus@reportstack.com


Information  Incidence of Diabetes in China  Market Share of Major Insulin Lispro Manufacturers in Sample Hospitals in China  Sales Price of Insulin Lispro in Hospital Market in China  Patent Status of Insulin Lispro in China  Production Status of Insulin Lispro in China  Major Insulin Lispro Enterprises in China  Prospect of China Insulin Lispro Market

Reportstack Contact contactus@reportstack.com


People recommended to purchase  Anti-diabetic Drug Manufacturers  Medical Institutions  Investors /Research Agencies Focusing on Anti-diabetic Drug Market

Reportstack Contact contactus@reportstack.com


If you are interested... 

Contact −

Sudha B

Email: contactus@reportstack.com

Ph:+1-888-789-6604

http://www.reportstack.com

Reportstack Contact contactus@reportstack.com

Investigation report on china insulin lispro market, 2009 2018  

According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 3...

Read more
Read more
Similar to
Popular now
Just for you